Suzuki, Katsuyoshi
Naito, Tateaki
Okayama, Taro
Yonenaga, Yusuke
Kitagawa, Midori
Sato, Rika
Suzuki, Keisuke
Ishii, Takeshi
Mitsuhashi, Noriko
Uehara, Ryusuke
Shimizu, Aruu
Nishizawa, Tamae
Fuseya, Hiroshi
Funding for this research was provided by:
Japan Agency for Medical Research and Development (21ck0106673h0001)
Article History
Received: 10 October 2022
Accepted: 22 December 2022
First Online: 5 January 2023
Declarations
:
: K.S. (Katsuyoshi Suzuki) and T.O. and Y.Y. and M.K. and R.S. and K.S. (Keisuke Suzuki) and T.I. and N.M. and R.U. and A.S. and T.N. (Tamae Nishizawa) and H.F have nothing to disclose. T.N. (Tateaki Naito) received a lecture fee from ONO Pharmaceutical CO. Ltd and Helsinn Healthcare SA and research funding from Otsuka Pharmaceutical CO. Ltd. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. The authors report no other conflicts of interest in this work.
: This project is a narrative review, and thus, ethics approval is not applicable.
: Not applicable to this narrative review.
: Not applicable to this narrative review.